Schizophrenia Research
Volume 84, Issue 2 , Pages 253-271 , June 2006

Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia

  • Rainald Schmidt-Kastner

      Affiliations

    • Department of Psychiatry and Neuropsychology, Division of Cellular Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands
    • European Graduate School of Neuroscience (EURON), The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Neuropsychology, Division of Cellular Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 43 3884108; fax: +31 43 3671096.
    • ,
  • Jim van Os

      Affiliations

    • European Graduate School of Neuroscience (EURON), The Netherlands
    • Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, Maastricht University, 6200 MD Maastricht, The Netherlands
    • Division of Psychological Medicine, Institute of Psychiatry, London, UK
    • ,
  • Harry W.M. Steinbusch

      Affiliations

    • Department of Psychiatry and Neuropsychology, Division of Cellular Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands
    • European Graduate School of Neuroscience (EURON), The Netherlands
    • ,
  • Christoph Schmitz

      Affiliations

    • Department of Psychiatry and Neuropsychology, Division of Cellular Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands
    • European Graduate School of Neuroscience (EURON), The Netherlands

Received 3 August 2005 ,Revised 27 February 2006 ,Accepted 28 February 2006.

References 

  1. Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, et al. A new role for Nogo as a regulator of vascular remodeling. Nat. Med. 2004;10:382–388
  2. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P. Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br. J. Psychiatry. 1993;163:522–534
  3. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD(67)), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol. Psychiatry. 2005;10:581–588
  4. Agid O, Shapira B, Zislin J, Ritsner M, Hanin B, Murad H, et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol. Psychiatry. 1999;4:163–172
  5. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 1995;52:258–266
  6. Albig AR, Schiemann WP. Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits MAP kinases and VEGF signaling. Mol. Biol. Cell. 2005;16:609–625
  7. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol. Psychiatry. 2005;58:85–96
  8. Anttila S, Kampman O, Illi A, Roivas M, Mattila KM, Lassila V, et al. NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. Psychiatr. Genet. 2003;13:61–64
  9. Arnold SE, Talbot K, Hahn CG. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog. Brain Res. 2004;147:319–345
  10. Ashe PC, Berry MD, Boulton AA. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 2001;25:691–707
  11. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 2004;77:858–866
  12. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 1999;19:819–834
  13. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001;7:569–574
  14. Bell R, Munro J, Russ C, Powell JF, Bruinvels A, Kerwin RW, et al. Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am. J. Med. Genet. 2000;96:736–743
  15. Benagiano V, Virgintino D, Rizzi A, Flace P, Troccoli V, Bormann J, et al. Glutamic acid decarboxylase-positive neuronal cell bodies and terminals in the human cerebellar cortex. Histochem. J. 2000;32:557–564
  16. Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, Willis A, et al. Functional consequences of PRODH missense mutations. Am. J. Hum. Genet. 2005;76:409–420
  17. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 2001;276:24232–24241
  18. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082–4090
  19. Bilton RL, Booker GW. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur. J. Biochem. 2003;270:791–798
  20. Blake DJ, Hawkes R, Benson MA, Beesley PW. Different dystrophin-like complexes are expressed in neurons and glia. J. Cell Biol. 1999;147:645–658
  21. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol. Psychiatry. 2001;6:79–82
  22. Bond A, Jones NM, Hicks CA, Whiffin GM, Ward MA, O'Neill MF, et al. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. 2000;294:800–809
  23. Bray NJ, Buckland PR, Owen MJ, O'Donovan MC. Cis-acting variation in the expression of a high proportion of genes in human brain. Hum. Genet. 2003;113:149–153
  24. Brown AS, van Os J, Driessens C, Hoek HW, Susser ES. Further evidence of relation between prenatal famine and major affective disorder. Am. J. Psychiatry. 2000;157:190–195
  25. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337–1340
  26. Brzustowicz LM, Simone J, Mohseni P, Hayter JE, Hodgkinson KA, Chow EW, et al. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am. J. Hum. Genet. 2004;74:1057–1063
  27. Buervenich S, Carmine A, Arvidsson M, Xiang F, Zhang Z, Sydow O, et al. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 2000;96:808–813
  28. Buka SL, Tsuang MT, Lipsitt LP. Pregnancy/delivery complications and psychiatric diagnosis. A prospective study. Arch. Gen. Psychiatry. 1993;50:151–156
  29. Camm EJ, Gibbs ME, Harding R, Mulder T, Rees SM. Prenatal hypoxia impairs memory function but does not result in overt structural alterations in the postnatal chick brain. Dev. Brain Res. 2005;160:9–18
  30. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev., Genet. 2003;4:710–720
  31. Chen YH, Tsai MT, Shaw CK, Chen CH. Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am. J. Med. Genet. 2001;105:753–757
  32. Chen WY, Shi YY, Zheng YL, Zhao XZ, Zhang GJ, Chen SQ, et al. Case-control study and transmission disequilibrium test provide consistent evidence for association between schizophrenia and genetic variation in the 22q11 gene ZDHHC8. Hum. Mol. Genet. 2004;13:2991–2995
  33. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al. Endothelial cell diversity revealed by global expression profiling. Proc. Natl. Acad. Sci. U. S. A. 2003;100:10623–20628
  34. Chiavetto LB, Boin F, Zanardini R, Popoli M, Michelato A, Bignotti S, et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry. 2002;15:480–484
  35. Cho H, Harrison K, Schwartz O, Kehrl JH. The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling. Biochem. J. 2003;371:973–980
  36. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet. 2002;11:1373–1380
  37. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13675–13680
  38. Church SM, Cotter D, Bramon E, Murray RM. Does schizophrenia result from developmental or degenerative processes?. J. Neural Transm., Suppl. 2002;63:129–147
  39. Cleaver O, Melton DA. Endothelial signaling during development. Nat. Med. 2003;9:661–668
  40. Dajas-Bailador FA, Lima PA, Wonnacott S. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology. 2000;39:2799–2807
  41. Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch. Gen. Psychiatry. 1999;56:234–240
  42. Dalman C, Thomas HV, David AS, Gentz J, Lewis G, Allebeck P. Signs of asphyxia at birth and risk of schizophrenia. Population-based case-control study. Br. J. Psychiatry. 2001;179:403–408
  43. Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531–4540
  44. Dupuy D, Aubert I, Duperat VG, Petit J, Taine L, Stef M, et al. Mapping, characterization, and expression analysis of the SM-20 human homologue, c1orf12, and identification of a novel related gene, SCAND2. Genomics. 2000;69:348–354
  45. Eastwood SL, Law AJ, Everall IP, Harrison PJ. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol. Psychiatry. 2003;8:148–155
  46. Edvinsson L, Krause DN. Catecholamines. In:  Edvinsson L,  Krause DN editor. Cerebral Blood Flow and Metabolism. Philadelphia: Lippincott Williams and Wilkins; 2002;p. 191–211
  47. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004;101:12604–12609
  48. Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lonnqvist J, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol. Psychiatry. 2004;9:1037–1041
  49. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004;36:131–137
  50. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54
  51. Freedman R. Schizophrenia. N. Engl. J. Med. 2003;349:1738–1749
  52. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, et al. Linkage disequilibrium for schizophrenia at the chromosome 15q13–14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am. J. Med. Genet. 2001;105:20–22
  53. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr. Genet. 2003;13:71–76
  54. Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J, et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 1998;52:173–185
  55. Goldberger C, Gourion D, Leroy S, Schurhoff F, Bourdel MC, Leboyer M, et al. Population-based and family-based association study of 5′ UTR polymorphism of the reelin gene and schizophrenia. Am. J. Med. Genet., B Neuropsychiatr. Genet. 2005;137:51–55
  56. Gross J, Leclere N, Heldt J, Muller I, Kietzmann T, Andreeva N. Differential effects of hypoxia on untreated and NGF treated PC12 cells. Life Sci. 2000;67:2595–2603
  57. Gu YZ, Hogenesch JB, Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 2000;40:519–561
  58. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98:4746–4751
  59. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic–inflammatory–vascular synthesis. BMC Med. Genet. 2005;6:7
  60. Harada S, Tachikawa H, Kawanishi Y. Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem. Biophys. Res. Commun. 2001;281:267–271
  61. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122:593–624
  62. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003;361:417–419
  63. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry. 2005;10:40–68
  64. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 2002;110:527–536
  65. Herzog Y, Guttmann-Raviv N, Neufeld G. Segregation of arterial and venous markers in subpopulations of blood islands before vessel formation. Dev. Dyn. 2005;232:1047–1055
  66. Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am. J. Pathol. 2003;62:575–586
  67. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 2002;27:1193–1200
  68. Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 2003;349:206–208
  69. Hong LE, Wonodi I, Avila MT, Buchanan RW, McMahon RP, Mitchell BD, et al. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am. J. Med. Genet., B Neuropsychiatr. Genet. 2005;136:8–11
  70. Honkaniemi J, Sharp FR. Global ischemia induces immediate-early genes encoding zinc finger transcription factors. J. Cereb. Blood Flow Metab. 1996;16:557–565
  71. Huang ST, Vo KC, Lyell DJ, Faessen GH, Tulac S, Tibshirani R, et al. Developmental response to hypoxia. FASEB J. 2004;18:1348–1365
  72. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, et al. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol. Psychiatry. 2004;56:698–700
  73. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998;95:15718–15723
  74. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13459–13464
  75. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum. Mol. Genet. 2002;11:2243–2249
  76. Jia Y, Yu X, Zhang B, Yuan Y, Xu Q, Shen Y, et al. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. Eur. Psychiatr. 2004;19:377–379
  77. Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 2000;48:257–261
  78. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, et al. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Mol. Psychiatry. 2000;5:323–326
  79. Junqueira R, Cordeiro Q, Meira-Lima I, Gattaz WF, Vallada H. Allelic association analysis of phospholipase A2 genes with schizophrenia. Psychiatr. Genet. 2004;14:157–160
  80. Kamnasaran D, Muir WJ, Ferguson-Smith MA, Cox DW. Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J. Med. Genet. 2003;40:325–332
  81. Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 2005;77:241–252
  82. Katsu T, Ujike H, Nakano T, Tanaka Y, Nomura A, Nakata K, et al. The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia. Neurosci. Lett. 2003;353:53–56
  83. Kendler KS. “A gene for….” The nature of gene action in psychiatric disorders. Am. J. Psychiatr. 2005;162:1243–1252
  84. Kietzmann T, Knabe W, Schmidt-Kastner R. Hypoxia and hypoxia-inducible factor modulated gene expression in brain: involvement in neuroprotection and cell death. Eur. Arch. Psychiatry Clin. Neurosci. 2001;251:170–178
  85. Kirov G, O'Donovan MC, Owen MJ. Finding schizophrenia genes. J. Clin. Invest. 2005;115:1440–1448
  86. Kitagawa H, Warita H, Sasaki C, Zhang WR, Sakai K, Shiro Y, et al. Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain. Neurosci. Lett. 1999;274:45–48
  87. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry. 2000;5:558–562
  88. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 2000;14:1343–1352
  89. Kreczmanski P, Schmidt-Kastner R, Heinsen H, Steinbusch HWM, Hof PR, Schmitz C. Stereologic studies of capillary length density in the frontal cortex of schizophrenics. Acta Neuropathol. 2005;109:510–518
  90. Krimer LS, Muly EC, Williams GV, Goldman-Rakic PS. Dopaminergic regulation of cerebral cortical microcirculation. Nat. Neurosci. 1998;1:286–289
  91. Kwon YT, Kashina AS, Davydov IV, Hu RG, An JY, Seo JW, et al. An essential role of N-terminal arginylation in cardiovascular development. Science. 2002;297:96–99
  92. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 2001;21:3995–4004
  93. Law AJ, Shannon Weickert C, Hyde TM, Kleinman JE, Harrison PJ. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience. 2004;127:125–136
  94. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK, et al. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev. Dyn. 2001;220:175–186
  95. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry. 2002;59:1085–1096
  96. Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 2001;105:749–752
  97. Leventhal C, Rafii S, Rafii D, Shahar A, Goldman SA. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol. Cell. Neurosci. 1999;13:450–464
  98. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 2002;25:409–432
  99. Lewis DA, Cruz D, Eggan S, Erickson S. Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia. Ann. N.Y. Acad. Sci. 2004;1021:64–76
  100. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV, et al. Systematic changes in gene expression in postmortem human brain associated with tissue pH and terminal medical conditions. Hum. Mol. Genet. 2004;13:609–616
  101. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry. 1999;46:729–739
  102. Lindvall O, Ernfors P, Bengzon J, Kokaia Z, Smith ML, Siesjoe BK, et al. Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proc. Natl. Acad. Sci. U. S. A. 1992;89:648–652
  103. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, Chen YJ, et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002;99:16859–16864
  104. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML, et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002;99:3717–3722
  105. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol. Cell. Biol. 2003;23:14–25
  106. Liu D, Jia H, Holmes DI, Stannard A, Zachary I. Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler. Thromb. Vasc. Biol. 2003;23:2002–2007
  107. Liverman CS, Cui L, Yong C, Choudhuri R, Klein RM, Welch KM, et al. Response of the brain to oligemia: gene expression, c-Fos, and Nrf2 localization. Mol. Brain Res. 2004;126:57–66
  108. Louissaint A, Rao S, Leventhal C, Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 2002;34:945–960
  109. Lu XC, Williams AJ, Yao C, Berti R, Hartings JA, Whipple R, et al. Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion. J. Neurosci. Res. 2004;77:843–857
  110. Mah S, Nelson MR, Delisi LE, Reneland RH, Markward N, James MR, et al. Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Mol. Psychiatry. 2006;(Apr 3 [Electronic publication ahead of print])
  111. Maltepe E, Simon MC. Oxygen, genes, and development: an analysis of the role of hypoxic gene regulation during murine vascular development. J. Mol. Med. 1998;76:391–401
  112. McGrath JJ, Pemberton MR, Welham JL, Murray RM. Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: a southern hemisphere study. Schizophr. Res. 1994;14:1–8
  113. Meyer J, Huberth A, Ortega G, Syagailo YV, Jatzke S, Mossner R, et al. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol. Psychiatry. 2001;6:302–306
  114. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 2002;22:2718–2729
  115. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000;9:1415–1423
  116. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RL, et al. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc. Natl. Acad. Sci. U. S. A. 2002;99:4680–4685
  117. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67
  118. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry. 2001;6:293–301
  119. Mousa A, Seiger A, Kjaeldgaard A, Bakhiet M. Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines. Cytokine. 1999;11:55–60
  120. Muglia P, Vicente AM, Verga M, King N, Macciardi F, Kennedy JL. Association between the BDNF gene and schizophrenia. Mol. Psychiatry. 2003;8:146–147
  121. Mukai J, Liu H, Burt RA, Swor DE, Lai WS, Karayiorgou M, et al. Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat. Genet. 2004;36:725–731
  122. Muntjewerff JW, Hoogendoorn ML, Kahn RS, Sinke RJ, Den Heijer M, Kluijtmans LA, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am. J. Med. Genet., B. Neuropsychiatr. Genet. 2005;135:69–72
  123. Murray RM, Sham P, van Os J, Zanelli J, Cannon M, McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr. Res. 2004;71:405–416
  124. Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y, et al. The human dihydropyrimidinase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol. Psychiatry. 2003;53:571–576
  125. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 1997;17:483–490
  126. Nelson MD, Saykin AJ, Flashman LA, Riordan HJ. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch. Gen. Psychiatry. 1998;55:433–440
  127. Novak G, Kim D, Seeman P, Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Mol. Brain Res. 2002;107:183–189
  128. Nsegbe E, Wallen-Mackenzie A, Dauger S, Roux JC, Shvarev Y, Lagercrantz H, et al. Congenital hypoventilation and impaired hypoxic response in Nurr1 mutant mice. J. Physiol. 2004;556:43–59
  129. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 2004;13:2699–2708
  130. O'Dwyer JM. Schizophrenia in people with intellectual disability: the role of pregnancy and birth complications. J. Intellect. Disabil. Res. 1997;41:238–251
  131. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry. 2004;9:14–27
  132. Ozeki Y, Tomoda T, Kleiderlein J, Kamiya A, Bord L, Fujii K, et al. Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. U. S. A. 2003;100:289–294
  133. Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, et al. Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr. Genet. 2004;14:147–150
  134. Palmen SJ, van Engeland H, Hof PR, Schmitz C. Neuropathological findings in autism. Brain. 2004;127:2572–2583
  135. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 2000;425:479–494
  136. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 2002;22:9771–9775
  137. Petronis A, Paterson AD, Kennedy JL. Schizophrenia: an epigenetic puzzle?. Schizophr. Bull. 1999;25:639–655
  138. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry. 2004;9:684–697
  139. Raghavendra Rao VL, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, et al. Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J. Neurochem. 2002;83:1072–1086
  140. Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, et al. Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia. J. Cereb. Blood Flow Metab. 2004;24:245–258
  141. Rees S, Inder T. Fetal and neonatal origins of altered brain development. Early Hum. Dev. 2005;81:753–761
  142. Rehn AE, Van Den Buuse M, Copolov D, Briscoe T, Lambert G, Rees S. An animal model of chronic placental insufficiency: relevance to neurodevelopmental disorders including schizophrenia. Neuroscience. 2004;129:381–391
  143. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet. 2000;96:196–201
  144. Roberts RC, Xu L, Roche JK, Kirkpatrick B. Ultrastructural localization of reelin in the cortex in post-mortem human brain. J. Comp. Neurol. 2005;482:294–308
  145. Rosenberg, R.N., Prusiner, S.B., DiMauro, S., Barchi, R.L., Nestler, E.J., 2003. The molecular and genetic basis of neurologic and psychiatric disease. Third Edition. Butterworth, Heinemann, Philadelphia.
  146. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 1999;277:H2205–H2211
  147. Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001;293:510–514
  148. Rybakowski JK, Borkowska A, Czerski PM, Dmitrzak-Weglarz M, Hauser J. The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology. 2004;47:115–119
  149. Sanjuan J, Toirac I, Gonzalez JC, Leal C, Molto MD, Najera C, et al. A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia. Eur. Psychiatr. 2004;19:349–353
  150. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002;296:692–695
  151. Schabitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 1997;17:500–506
  152. Schmidt-Kastner R, Truettner J, Lin B, Zhao W, Saul I, Busto R, et al. Transient changes of brain-derived neurotrophic factor (BDNF) mRNA expression in hippocampus during moderate ischemia induced by chronic bilateral common carotid artery occlusions in the rat. Mol. Brain Res. 2001;92:157–166
  153. Schmidt-Kastner R, Zhang B, Belayev L, Khoutorova L, Amin R, Busto R, et al. DNA microarray analysis of cortical gene expression during early recirculation after focal brain ischemia in rat. Mol. Brain Res. 2002;108:81–93
  154. Schmidt-Kastner R, Zhang BT, Zetterstrom RH, Kietzmann T, Aguirre-Chen C, Saul I, et al. Nurr1 mRNA upregulation after global brain ischemia in rat in relation to HIF-1. J. Cereb. Blood Flow Metab. 2003;23(Suppl. 1):383
  155. Schmidt-Kastner R, Aguirre-Chen C, Saul I, Yick L, Hamasaki D, Busto R, et al. Astrocytes react to oligemia in the forebrain induced by chronic bilateral common carotid artery occlusion in rats. Brain Res. 2005;1052:28–39
  156. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC, et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol. Psychiatry. 2004;9:203–207
  157. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, et al. Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia. Schizophr. Res. 2003;65:19–25
  158. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 2003;72:185–190
  159. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999;15:551–578
  160. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001;13:167–171
  161. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 2001;49:1–52
  162. Shyu WC, Lin SZ, Chiang MF, Yang HI, Thajeb P, Li H. Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol. Aging. 2004;25:935–944
  163. Spatz M, Kaneda N, Sumi C, Nagatsu I, Creveling CR, Nagatsu T. The presence of catechol-o-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells. Brain Res. 1986;381:363–367
  164. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. 1998;251:189–192
  165. St. Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet. 1990;336:13–16
  166. Stefanis NC, van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Hantoumi I, et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry. 2004;56:510–515
  167. Stefanis NC, van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Stefanis CN. Tuning rather than improving performance: The effect of COMT Val158Met Polymorphism on CPT-IP. Am. J. Psychiatry. 2005;162:1752–1754
  168. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002;71:877–892
  169. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am. J. Hum. Genet. 2003;72:83–87
  170. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 2002;71:337–348
  171. Susser E, Neugebauer R, Hoek HW, Brown AS, Lin S, Labovitz D, et al. Schizophrenia after prenatal famine. Further evidence. Arch. Gen. Psychiatry. 1996;53:25–31
  172. Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr. Res. 2003;65:15–18
  173. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Suzuki T. Linked polymorphisms (−333G>T and −286A>G) in the promoter region of the CCK-A receptor gene may be associated with schizophrenia. Psychiatry Res. 2001;103:147–155
  174. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Transactivation mechanisms of mouse clock transcription factors, mClock and mArnt3. Genes Cells. 2000;5:739–747
  175. Takahata S, Sogawa K, Kobayashi A, Ema M, Mimura J, Ozaki N, et al. Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and clock. Biochem. Biophys. Res. Commun. 1998;248:789–794
  176. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 2004;113:1353–1363
  177. Tan EC, Chong SA, Wang H, Chew-Ping Lim E, Teo YY. Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Mol. Brain Res. 2005;139:212–216
  178. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, et al. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J. 2002;16:1465–1467
  179. Tissir F, Goffinet AM. Reelin and brain development. Nat. Rev., Neurosci. 2003;4:496–505
  180. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798–805
  181. Tochigi M, Zhang X, Umekage T, Ohashi J, Kato C, Marui T, et al. Association of six polymorphisms of the NOTCH4 gene with schizophrenia in the Japanese population. Am. J. Med. Genet. 2004;128B:37–40
  182. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol. Psychiatry. 2004;55:346–352
  183. Tsuang M. Schizophrenia: genes and environment. Biol. Psychiatry. 2000;47:210–220
  184. Ueda H, Baba T, Terada N, Kato Y, Fujii Y, Takayama I, et al. Immunolocalization of dystrobrevin in the astrocytic endfeet and endothelial cells in the rat cerebellum. Neurosci. Lett. 2000;283:121–124
  185. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry. 2002;7:515–518
  186. Utsugisawa K, Nagane Y, Obara D, Tohgi H. Increased expression of alpha7 nAChR after transient hypoxia in PC12 cells. NeuroReport. 2000;11:2209–2212
  187. Van Erp TG, Saleh PA, Rosso IM, Huttunen M, Lonnqvist J, Pirkola T, et al. Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers. Am. J. Psychiatry. 2002;159:1514–1520
  188. van Os J, Selten JP. Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. Br. J. Psychiatry. 1998;172:324–326
  189. van Os J, Sham P. Gene-environment interactions. In:  Murray RM,  Jones PB,  Susser E,  van Os J,  Cannon M editor. The Epidemiology of Schizophrenia. Cambridge: Cambridge University Press; 2003;p. 235–254
  190. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan DM, et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 2001;55:641–650
  191. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res. 2002;58:11–20
  192. Vawter MP, Shannon Weickert C, Ferran E, Matsumoto M, Overman K, Hyde TM, et al. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem. Res. 2004;29:1245–1255
  193. Veenstra-VanderWeele J, Cook EH. Molecular genetics of autism spectrum disorder. Mol. Psychiatry. 2004;9:819–832
  194. Verma R, Mukerji M, Grover D, B-Rao C, Das SK, Kubendran S, et al. MLC1 gene is associated with schizophrenia and bipolar disorder in Southern India. Biol. Psychiatry. 2005;58:16–22
  195. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase 67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry. 2000;57:237–245
  196. Waddington JL, Buckley PF, Scully PJ, Lane A, O'Callaghan E, Larkin C. Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics?. J. Psychiatr. Res. 1998;32:179–189
  197. Wei J, Hemmings GP. The NOTCH4 locus is associated with susceptibility to schizophrenia. Nat. Genet. 2000;25:376–377
  198. Weidenhofer J, Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone. Mol. Cell. Neurosci. 2006;31:243–250
  199. Wieland T, Mittmann C. Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol. Ther. 2003;97:95–115
  200. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S, et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol. Psychiatry. 2003;8:485–487
  201. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683–690
  202. Xu J, Pato MT, Torre CD, Medeiros H, Carvalho C, Basile VS, et al. Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am. J. Med. Genet. 2001;105:669–674
  203. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X, et al. Association study of the human FZD3 locus with schizophrenia. Biol. Psychiatry. 2003;54:1298–1301
  204. Yin XH, Zhang QG, Miao B, Zhang GY. Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. J. Neurochem. 2005;93:1021–1029
  205. Yu L, Yang MS, Zhao J, Shi YY, Zhao XZ, Yang JD, et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr. Res. 2004;71:179–183
  206. Zhai QH, Futrell N, Chen FJ. Gene expression of IL-10 in relationship to TNF-alpha, IL-1beta and IL-2 in the rat brain following middle cerebral artery occlusion. J. Neurol. Sci. 1997;152:119–124
  207. Zheng Y, Li H, Qin W, Chen W, Duan Y, Xiao Y, et al. Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun. 2005;328:809–815
  208. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541–1545
  209. Zhou C, Li Y, Nanda A, Zhang JH. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem. Biophys. Res. Commun. 2003;309:368–376
  210. Zornberg GL, Buka SL, Tsuang MT. Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study. Am. J. Psychiatry. 2000;157:196–202

PII: S0920-9964(06)00111-3

doi: 10.1016/j.schres.2006.02.022

Schizophrenia Research
Volume 84, Issue 2 , Pages 253-271 , June 2006

Article Tools